GUEST COLUMNISTS

• The Second Wave Of Biosimilars: New Scenarios, New Rules

  The arrival of what we could call the first “bio patent cliff” has revealed important lessons that should be taken into consideration when selecting new candidates for the second and third waves.

• Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19

  Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.

• Nephrology Sector Of The Immunology Market: A Major Biopharma Development Opportunity

  Most of the development in immunology to date has happened in rheumatologic, dermatologic, and respiratory indications. Nephrology, on the other hand, the medical branch that focuses on kidney diseases, has few approved treatment options outside of those that are expensive and higher risk, such as dialysis and transplants. 

• Biologics Manufacturing In China: Competition Heats Up Among CMOs & Their Clients

  Significant growth of outsourced commercial-scale manufacturing is projected for the near future in China, though certain bottlenecks remain.

• Mammalian Biomanufacturing Industry Supply & Demand Trends

  While capacity will increase over the next five years, demand for capacity—pandemic aside—will increase at a slightly faster rate. This increase will allow for some short-term loosening of capacity constraints, but after 2024, capacity tightening may occur.

• Will Biosimilar Manufacturers Pursue Lower-Revenue Products?

  Will biosimilar makers have any motivation to develop biosimilar competitors for biologics earning considerably less in U.S. sales than previous generations? Biosimilar Development decided to do a deeper dive into one of these products, which may represent a broader base of biologic agents beyond autoimmune and oncology agents.

• Interacting With FDA During Biosimilar Development: From Initial Advisory Meeting To BLA

  In Part 2 of this two-part article, we discuss what information is critical to support the sponsor’s argument that the proposed product is biosimilar to the designated reference product and when is it appropriate and at what level of detail it should be for each stage of interaction with the FDA.